New Perspectives in AF and PCI: Implications for the Practicing Physician.

Slides:



Advertisements
Similar presentations
Denise Sutter, PharmD, BCPS
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Addressing the Challenges in Primary and Secondary Stroke Prevention
Covering the Bases in Cardioversion
European and US Guidelines
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
Preventing Thrombotic Complications in ACS: State of the Art
Atrial Fibrillation and PCI
Anticoagulants in Interventional Cardiology:
Updates in Anticoagulation: What Did We Learn From ESC 2017?
US Guidelines US Guidelines Low-risk Patients.
NOACs, AF, and PCI: What Do the Latest Data Suggest?
Achieving Long-Term Protection Post-MI
When Is Adding Aspirin to NOACs Worth the Risk?
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
NOACs in Clinical Practice: Are They All the Same?
Dual Goals for the Management of Stable Ischemic Heart Disease (SIHD)
A New Era for NOACs:.
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Introduction Antiplatelet Agents ADP Receptor Antagonists.
Managing Complex Hypertension: What Every Physician Should Know
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
New Perspectives in CAD and PAD: Weighing the Latest Evidence
What Has Been Tried and What Is True?
Understanding Statin Metabolism
Surveying the Safety of NOACs in the Real World
How and When to Decide on Revascularization in Stable Ischemic Heart Disease.
Selecting NOACs for High-Risk Patients
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
The Essentials for Secondary Stroke Prevention
Learning Objectives PLATO Primary Efficacy End Point CV Death, MI, or Stroke.
NOACS: Emerging data in ACS/IHD
Efficacy and Safety of Edoxaban in Patients With AF and HF
AF and PCI in Practice.
TAVR and the Risk of Thrombosis
Watching for the Patient With AF: Latest Advances and Technologies
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Oral Anticoagulation in AF
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Atrial Fibrillation.
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Updates in Heart Failure:
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Identifying High-Risk AF Patients
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies
Cancer-Associated Thrombosis
Updates in Anticoagulation: Key Sessions at ESC 2017
Antithrombotics in Arterial Disease: Focus on Coronary Disease
Program Goals Background: Anticoagulation in Patients With VTE.
NOACs in CAD.
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
5 Good Minutes on Atrial Fibrillation-related Stroke
Extraordinary Cases in Stroke Prevention
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
In the Know.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

New Perspectives in AF and PCI: Implications for the Practicing Physician

Program Goals

Overview

WOEST Study Design

WOEST Bleeding and Thrombotic Events

PIONEER AF-PCI Study Design

PIONEER AF-PCI Clinically Significant Bleeding

PIONEER AF-PCI MACE

PIONEER AF-PCI Post Hoc Analysis Recurrent Hospitalization

RE-DUAL PCI Trial Design

RE-DUAL PCI ISTH Major or CRNM Bleeding

RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization

RE-DUAL PCI TIMI Major Bleeding and ICH

Triple vs Dual Therapy in AF and PCI: Meta-Analysis

Triple Therapy May Still Be Needed in Some Patients

AUGUSTUS Study Design

ENTRUST-AF PCI Study Design

NOAC Dose

RENAL-AF Study Design

Individualization of Therapy

Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)